Closed · RFA-FD-13-014 · CFDA 93.103 · Discretionary
Development of in vivo predictive dissolution method for orally inhaled drug products
Federal grant opportunity posted by Food and Drug Administration, cataloged on Grants.gov.
- $200K-$200K
- Award range
- Closed
- Status
- July 2, 2013
- Close date
- 7
- Expected awards
The verdict
Development of in vivo predictive dissolution method for orally inhaled drug products is a closed discretionary listing from Food and Drug Administration that offered $200,000 -- $200,000 across 7 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 481 other opportunities from Food and Drug Administration.
- $200K-$200K
- award range
- Closed
- application status
- 7
- expected awards
- 93.103
- CFDA program
Archived opportunity record
Development of in vivo predictive dissolution… is closed (last close July 2, 2013). The parent program page for CFDA 93.103 is the reliable place to catch re-announcements. Food and Drug Administration still indexes 481 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed July 2, 2013
Est. Total Funding
$60,000
Expected Awards
7
Instrument
Cooperative Agreement
Description
Clinical performance of orally inhaled drug products (OIDPs) depends not only on regional drug deposition in the lung but also on in vivo drug dissolution rate, thereby affecting local availability of the drug at sites of action in the lung as well as rate and extent of the drug absorption from the lung. An ideal dissolution method for inhalation products should take into account various biological and physicochemical factors including, but not limited to, scarce lung lining fluid available for drug dissolution, presence of endogenous lung surfactants, mass of drug deposited per unit surface area of lung and inter-particulate interactions of the depositing particles. Several attempts have been made to develop dissolution methods for characterization of OIDPs; however, none of the methods captures all the key factors described above and the methods developed have not been shown to be predictive of in vivo dissolution. In order to provide better prediction of drug dissolution within the lung, it is necessary to develop a dissolution method that accounts for relevant biological and physicochemical factors that impact drug dissolution in vivo. In 2011, OGD initiated a study titled “Pharmacokinetics of Locally Acting Orally Inhaled Drug Products” to evaluate the sensitivity of PK to differences in the aerodynamic particle size distribution (APSD) for three different formulations of an inhaled corticosteroid (fluticasone propionate, FP) dry powder inhaler (DPI). As differences in PK may result due to factors including, but not limited to, differences in dissolution rate of the formulations, it would be preferable to study the dissolution of the these formulations and incorporate this information to build a model to link regional lung deposition to PK. Objective The goal of this project is to develop an in vitro dissolution method for OIDPs which will be capable of predicting in vivo dissolution of drugs that are administered via the inhalation route. The results obtained from this study will be used to gain better understanding of the formulation factors that impact dissolution and thereby in vitro-in vivo relationships for orally inhaled drugs. This investigation will constitute a significant step towards gaining a better understanding of relationship among OIDP formulations and local availability (efficacy) and pharmacokinetics (PK, safety). The outcome of the project will aid in development of a quality-by-design (QbD) tool that could be used for formulation development and optimization as well as product quality control. Detailed Description A predictive dissolution model will be developed to study the effect of formulation factors (API particle size, formulation composition, etc.) on dissolution of aerosolized drug particles. This investigation will consist of 3 phases: Phase 1: Development/ modification of existing dissolution methods for OIDPs, by accounting for mass of drug deposited per unit surface lung area, limited lung lining fluid and other factors that may impact drug dissolution in vivo. Phase 2: Selection of OIDPs for dissolution study. OIDPs should be selected to represent a range of physicochemical properties of the API (e.g., solubility, particle size, crystallanity, lipophilicity, adhesive/cohesive properties). The selected OIPDs should represent solution and suspension-based metered dose inhalers, and DPIs. OGD’s research FP formulations will be provided for the study. Phase 3: Development of a mathematical model to describe a relationship between the in vitro dissolution data and PK.
Wide-open applicant board · 14 Grants.gov doors
Development of in vivo predictive dissolution… prints 14 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +10 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Science and Technology / R&D (HL;ST). Only 8 other Food and Drug Administration listings share this exact eligibility-code string (2% of 482).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 04
- Special district governments
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 08
- Public / Indian housing authorities
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Food and Drug Administration Research
U.S. Department of Health and Human Services
Agency Contact
Gladys Melendez-Bohler Grants Management Specialist Phone 301-827-7175
More from Food and Drug Administration
Federal and University Partnership to Improve the Safety of Seafood from the Gulf of America
Research, Education, and Outreach on Botanical Natural Products
Cooperative Agreement to Support Shellfish Safety Assistance Project
Education and Outreach to Tribal Producers through the Tribal Food Safety Alliance
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
What to do next
Development of in vivo predictive dissolution… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.103 may publish future NOFOs under the same assistance listing. Open program
- Food and Drug Administration Research indexes 42 Grants.gov listings in this extract. Program profile
- Food and Drug Administration lists 481 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |